Levodopa is the most efficacious agent for the treatment of motor features of Parkinson's disease but its chronic use is associated with the development of motor complications. Mounting evidence ...

Combining levodopa with a DDC inhibitor (DDCI), such as carbidopa or benserazide, greatly reduces the incidence of nausea and vomiting, increases the levodopa half-life from approximately 60 to 90 ...